期刊
CELLS
卷 10, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/cells10030648
关键词
prognostic; gene expression signature; breast cancer; hepatocellular carcinoma; colorectal cancer
类别
资金
- Clinician Scientist programme Interfaces and Interventions in Chronic Complex Conditions - DFG [EB 187/8-1]
- Ministry of Science, Research and Arts of the State of Baden-Wurttemberg
- Sino German Center for Research Promotion [C-0012, GZ 1546]
Current cancer staging systems based on anatomical extent need refinement by biological parameters to improve patient stratification for tumor therapy or surveillance. Advances in genomic technologies allow detailed exploration of molecular tumor characteristics and potential classification of tumor subgroups by biological determinants. Despite numerous prognostic gene signatures, only a few have advanced to clinical implementation.
Current staging systems of cancer are mainly based on the anatomical extent of disease. They need refinement by biological parameters to improve stratification of patients for tumor therapy or surveillance strategies. Thanks to developments in genomic, transcriptomic, and big-data technologies, we are now able to explore molecular characteristics of tumors in detail and determine their clinical relevance. This has led to numerous prognostic and predictive gene expression signatures that have the potential to establish a classification of tumor subgroups by biological determinants. However, only a few gene signatures have reached the stage of clinical implementation so far. In this review article, we summarize the current status, and present and future challenges of prognostic gene signatures in three relevant cancer entities: breast cancer, colorectal cancer, and hepatocellular carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据